Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
April 2015—Qiagen announced the CE-IVD marking of its novel liquid biopsy-based companion diagnostic that analyzes circulating nucleic acids obtained from blood samples to assess a genomic mutation in patients with non-small cell lung cancer.
April 2015—Applied Spectral Imaging has received FDA clearance for its GenASIs HiPath image capture and analysis platform. The ASI platform for immunohistochemistry samples integrates with existing lab microscopes and workflows, aiming to provide labs with a cost-effective solution for digital pathology.
April 2015—Biocartis announced it is in the testing phase of a Rapid Ebola Virus Triage Test that it is developing in association with Janssen Diagnostics and the Institute for Tropical Medicine in Antwerp, Belgium, for its Idylla system, a CE-IVD-marked, fully automated molecular diagnostic platform.
April 2015—The Clinical and Laboratory Standards Institute released a new edition of its annual supplement “Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement (M100-S25).” This document provides the revised breakpoints, new testing recommendations, and reporting changes needed to incorporate into routine practice for improving detection and reporting of antimicrobial resistance.
April 2015—Illumina has launched the HiSeq X Five System and HiSeq 3000/4000 systems and has introduced the NextSeq 550 System, an NGS system enabled for array scanning. The HiSeq X Five System is designed for laboratories wanting to take advantage of HiSeq X technology for human whole genome sequencing at a smaller scale. At full utilization, the system, which consists of five individual HiSeq X instruments, provides the throughput to sequence more than 9,000 genomes a year.
April 2015—The Dysis Advanced Cervical Imaging System, a computerized diagnostic tool designed to assist in the early detection of cancerous and precancerous cervical lesions, is available from Dysis Medical in the U.S. after undergoing testing and review in Europe.
April 2015—The Binding Site, through its arrangement with Arotec Diagnostics, offers an Ro (SSA) antigen designed for use as a component in solid phase ELISA-based immunoassay test procedures for the detection of anti-Ro (SSA) antibodies for use in research and in vitro diagnostic manufacturing applications.
April 2015—Genologics announced that GenomeDx Biosciences has implemented Genologics’ laboratory information management system, Clarity LIMS, to support whole transcriptome analysis workflows as part of GenomeDx’s mission to address unmet clinical needs in the management of prostate cancer. Headquartered in Vancouver, BC, GenomeDx will use Clarity LIMS in its CLIA-certified lab in San Diego.
April 2015—The NanoZoomer-SQ from Hamamatsu is a compact, single slide desktop scanner that converts a glass slide into a high-resolution digital image.
April 2015—The Clinical and Laboratory Standards Institute has published “Quality System Regulation for Laboratory-Developed Tests: A Practical Guide for the Laboratory.” The guide is intended to clarify how to implement the Quality System Regulation, 21 CFR 820, that may be required for some classifications of LDTs.
